NIH is hopeful the research will enable doctors to detect signs of stroke damage earlier, opening the door for them to initiate treatments in a timelier manner.

Experts say these new findings highlight the need for more effective screening initiatives among men who may face access barriers. 

The system was built with patients in mind, and its compact design has the potential to expand access to the modality where it may have previously been lacking. 

When used topically, the agent penetrates the skin and generates a fluorescent signal under the guidance of a fluorescent confocal microscope.

When used during surgery, it can help providers identify cancerous lesions that are not in their immediate vision. 

Greg Piefer, PhD, chief executive and founder of SHINE, a Wisconsin-based radiopharmaceutical company that is building the world’s largest medical isotope production facility in Janesville, Wisconsin, explains progress on the company's fusion reactor that will become the first U.S. commercial supplier of molybdenum-99 in decades.

A new study is the first to show that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT prior to salvage therapy have improved survival rates. 

The U.S. Food and Drug Administration has accepted a New Drug Application for a new formulation of a commercially available PSMA imaging agent.